Protocol Numb	er: NID	A-CPU-(0003							Site	lden	tification	Numb	er: 980101	7
RPR 102681 - C						7						tification		· · ·	1
Study Day	UN	ISCHD				_				D	ate:		/	/	Ī
							Form No	ot Done				(mm)	(dd)	(уууу)	
					ADJ	ECTI	VE SCA	LE							
For each item pro	esented,	indicate H	OW YOU I	FEEL RIC	GHT NOW.										_
								_			╽┍				
		<u> </u>											<u> </u>		
	_								_				,		
					<u> </u>	\top					<u> </u>		<u> </u>		
\perp	Ī						_		_		_		_		
											<u> </u>				
	7									_					
						<u> </u>		<u> </u>				<u> </u>			
						耳									
	-														
						<u> </u>		<u> </u>							
						_					<u> </u>				
<u>-</u>															
				_		\neg					Г				

Time Interval	1. Fearful	2. Feeling of Power	3. Stomach Upset	4. Suspicious	5. Sweating	6. Dizzy
65 minutes						
7. Craving for cocaine	8. Seeing	9. Irritable	10. Sleepy 11. T	remor 12. Thi	13. Excited	d 14. Jittery
15. Tingling 16. Di	y Mouth 17. Fi	dgety 18. Feel a TI	hrill 19. Nervous	20. Stimulated	21. Drug Effect	22. Numbness
75 minutes	1. Fearful	2. Feeling of Power	3. Stomach Upset	4. Suspicious	5. Sweating	6. Dizzy
7. Craving for cocaine	8. Seeing	9. Irritable	10. Sleepy 11. T	remor 12. Thi	irsty 13. Excited	d 14. Jittery
15. Tingling 16. Di	y Mouth 17. Fi	dgety 18. Feel a TI	hrill 19. Nervous	20. Stimulated	21. Drug Effect	22. Numbness
Time Interval 85 minutes	1. Fearful	2. Feeling of Power	3. Stomach Upset	4. Suspicious	5. Sweating	6. Dizzy
7. Craving for cocaine	8. Seeing	9. Irritable	10. Sleepy 11. T	remor 12. Thi	irsty 13. Excited	d 14. Jittery
15. Tingling 16. Di	y Mouth 17. Fi	dgety 18. Feel a TI	hrill 19. Nervous	20. Stimulated	21. Drug Effect	22. Numbness
Time Interval 95 minutes	1. Fearful	2. Feeling of Power	3. Stomach Upset	4. Suspicious	5. Sweating	6. Dizzy
7. Craving for cocaine	8. Seeing	9. Irritable	10. Sleepy 11. T	remor 12. Thi	irsty 13. Excited	d 14. Jittery
15. Tingling 16. Di	y Mouth 17. Fi	dgety 18. Feel a TI	hrill 19. Nervous	20. Stimulated	21. Drug Effect	22. Numbness
	Sc	ource Completed By ((Initials):			
						ADJSCALE

rotocol Number: NID				ication Number				
PR 102681 - Cocaine			;	Subject Identif	ication Number	: 0050		
tudy Day	ISCHD				Date:	/ (dd)	/ 	
			Form Not	Done	· ·	illi) (dd)	(333).	
ADJECTIVE SCALE								
Actual Time:		(00:00 - 23:59)						
For each item preser	nted, indicate HOW YOU	FEEL RIGHT NO	DW.					
		Not at all	A little bit	Moderately	Quite a bit	Extremely		
		0	1	2	3	4		
		0	1	2	3	 4		

□ 0	1	<u> </u>	■ 3	4	
□ 0	1	<u> </u>	3	4	
□ 0	1	<u> </u>	3	4	
□ 0	1	<u> </u>	3	4	
□ 0	1	<u> </u>	3	4	
□ 0	1	<u> </u>	3	4	
	1	<u> </u>	3	4	
	1	<u> </u>	3	4	
	1	<u> </u>	3	4	
	1	<u> </u>	3	4	
	1	<u> </u>	□ 3	4	
	1	<u> </u>	3	a 4	
	1	<u> </u>	■ 3	4	
	1	<u> </u>	3	a 4	
	1	<u> </u>	■ 3	4	
	1	<u> </u>	■ 3	4	
□ 0	1	<u> </u>	□ 3	4	
□ 0	1	<u> </u>	□ 3	4	
□ 0	1	<u> </u>	□ 3	4	
□ 0	1	<u> </u>	□ 3	4	
□ 0	1	<u> </u>	□ 3	4	
□ 0	1	<u> </u>	3	4	

Source Completed By (Initials):	

102681 - Cocaine	Interaction			Subject Identifica	ntion Number:
Day UN	SCHD			•	
		ADVEF	RSE EVENTS		
Has the subject	et had any Adverse E	vents during this study?		Yes No If yes, please	se list all Adverse Events belov
Severity	Study Drug Relationship	Action Taken Regarding Investigational Agent			Serious
1 = Mild 2 = Moderate 3 = Severe	1 = Definitely 2 = Probably 3 = Possibly 4 = Remotely 5 = Definitely Not 6 = Unknown	 1 = None 2 = Discontinued Perm. 3 = Discontinued Temp. 4 = Reduced Dose 5 = Increased Dose 6 = Delayed Dose 	1 = None 2 = Remedial Therapy-pharm 3 = Remedial Therapy-nonpharm 4 = Hospitalization	1 = Resolved, No Sequelae 2 = AE still present - no tx 3 = AE still present - being tx 4 = Residual effects present-no tx 5 = Residual effects present-tx 6 = Death 7 = Unknown	1 = Yes 2 = No (If yes, complete SAE form)
# 1	EVENT Severity Relatedn	Start Date (mm) (dd) ess Action Taken Oth	(yyyy) (mm) Outcome	continuity (dd) (yyyy) Serious Init	
				Yes No	

Protocol Number:	NIDA	A-CPU-000	03				Site Ide	entificati	ion Number	980101
RPR 102681 - Coca	aine	Interactio	n				Subject Ide	entificati	ion Number	: 0050
Study Day	UN	SCHD			Forr	m Not Done	Date	(mm)	/ (dd)	(уууу)
				ALCC	HOL BRE	ATHALYZER TEST]		
	1)	Was alcoh	ol breath	alyzer test p	erformed?		Yes	No	Unknown	
	2)	Date alcol	nol breath	ol breathalyzer test performed				/ (dd)	(уууу)	
	3)	Blood Alco	hol Conte	ent (BAC):					(mg/ml)	
	4)	Provide co	mments	for any action	on taken:					
		Source C	ompleted	By (Initials)						ALBREATH v1

Protocol Number: NIDA-CPU-0003		Site Identification Number: 980101
RPR 102681 - Cocaine Interaction		Subject Identification Number: 0050
Study Day UNSCHD	Form Not Done	Date: (mm) / (dd) / (yyyy)
		(mm) (dd) (yyyy)
	ARCI SHORT FORM	
These 49 items may or may not describe h F (for FALSE) for each item that does not of	ow you feel right now. Mark T (for TRUE) next to escribe how you feel.	each item that does describe how you feel, and
Time Interval:		
Time Interval:		
	0	
		0
	0	0 0
	0) 0
	0	0
	0) 0
	0	0 0
) 0
) 0
	0	
	0	
	0	
	C	
	0	
	0) 0
	С) 0
		0
	0) 0
	0) 0
<u></u>		

L

27. Less discouraged	True	False
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0
	0	0

Source Completed By (Initials):	

ARCI v1

Protocol Number: NIDA-CPU-000	3					Site Identif	ication N	umber: 980101
RPR 102681 - Cocaine Interaction				Sul	oject Identif	ication N	umber: 0050	
Study Day UNSCHD			Form Not I	Done		Date:	nm) /	(dd) (yyyy)
						(ı	···· <i>i</i>	(dd) (yyyy)
		BRIEF	PSYCHIAT	TRIC RAT	ING SCAL	E		
Actual Time:	(00:00 - 2	23:59)				Time In	iterval:	
SYMPTOMS	Not Assessed	Not Present	Very Mild	Mild	Moderate	Moderately Severe	Severe	Extremely Severe
1-Somatic Concern	■ NA	□ 1	2	3	4	5	6	7
	Source	e Complete	d By (Initials)):				BPRSTIME v1

Protocol Number: NIDA-CPU-00	003			Site Identification Number: 980101
RPR 102681 - Cocaine Interaction	on			Subject Identification Number: 0050
Study Day UNSCHD		Form Not Don	e 🗌	Date: / / / / (dd) / (yyyy)
	В	RIEF PHYSICAL	EXAM	
Temperature: (oral) Pulse Rate	beats/minut	_	atory Rate Pressure	breaths/minute / mm/hg
General Exam	Normal Abnorm	Abnormal al Significant	<u>Not</u> <u>Done</u>	If Abnormal, explain below
Neurological				
Cardiovascular				
Respiratory				
Gastrointestinal				
Skin				
Other, specify:				
	Soul	rce Completed By (I	nitials):	BRIEFPE v1

Protoc	ol Nun	ber: NIE	A-CPU-00	03				Site I	dentifica	ation Number	980101
RPR 1	02681 -	Cocaine	Interaction	n	<u></u>			Subject I	dentifica	ation Number	: 0050
Study	Day	10	ISCHD			Form No	ot Done	Da	ate:	m) (dd)	/ (2000)
									(1111	(du)	(уууу)
				BF	RIEF SU	JBSTANCE CR	AVING SCALE	(BSCS)			
1)	The INT	ENSITY of	my craving,	that is, how muc	h I desire	d cocaine in the pas	st 24 hrs was:				
2)	The FRI	EQUENCY o	of my craving	that is, how oft	en I desir	ed cocaine in the pa	ast 24 hrs was:				
3)	The LEN	NGTH of tim	ne I spent in o	raving for cocair	ie during t	the past 24 hrs was:	:		ĺ		
4)	Write in	the NUMB	ER of times ye	ou think you had	craving fo	or cocaine during the	e past 24 hours:		ĺ		
5)	Write in	the total T	IME spent cra	ving cocaine dur	ing the pa	st 24 hours:		HOURS		MINUTE	S
6)	WORST	day: Durir	ig the past w	eek my most inte	ense cravi	ng occurred on the	following day:		_		
	7) T	he date fo	r that day wa	s:	/	/ (n	nm/dd/yyyy)		(If "All day	s the same, then skip t	to Question #8)
8)	The IN	TENSITY of	my craving,	that is, how mu	ch I desire	ed cocaine on that \	WORST day was:				
9)	A 2nd c	raved drug	during the pa	st 24 hours was:							_
									r	Other (specif	y)
10)	The INT	ENSITY of	my craving,	hat is, how muc	h I desired	d this second drug i	n the past 24 hrs w	ras:			
11)	The FRI	EQUENCY o	of my craving,	that is, how often	en I desire	ed this second drug	in the past 24 hrs	was:	Ì		
12)	The LEN	IGTH of tim	ne I spent in o	raving for this se	econd drug	g during the past 24	hrs was:		j		
13)	A 3rd cr	aved drug	during the pa	st 24 hours was:							
										Other (specif	y)
14)	The INT	ENSITY of	my craving,	hat is, how muc	h I desired	d this third drug in t	the past 24 hrs was	:			
15)	The FRE	EQUENCY o	f my craving,	that is, how often	en I desire	ed this third drug in	the past 24 hrs wa	is:			
16)	The LEN	IGTH of tim	ne I spent in c	raving for this th	ird drug d	luring the past 24 hr	rs was:				
				Source	ce Com _l	pleted By (Initi	als):				BSCS v1

	mber: NIDA-CPU-0003 - Cocaine Interaction				Site Identificati Subject Identificati	
tudy Day	UNSCHD				Date:	/
					(mm)	(dd
		COCA	INE TIMELINE	FOLLOW	BACK	
	Consent Date:	/	(mm/d	d/yyyy)		
	Date 30 Days Prior to				(mm/dd/yyyy)	
<u> </u>					(
Day	1 is yesterday, Day 2 is the	e day before y	resterday, etc.			
<u> </u>	<u> </u>					
		0	0	0	0	
		0	0	0	0	
		0	0	0	<u> </u>	
		0	0	0	<u> </u>	
			0	0	<u> </u>	
		0	0	0	0	
		0	0	0	0	
		0	0	0	0	
		0	0	0	0	
		0	0	0	0	
		0	0	0	0	
		0	0	0	0	
		0	0	0	0	
		0	0	0	0	
		0	0	0	0	
		0	0	0	0	
		. 0	0	-	0	
		0	0		0	
		0	0	0	0	
		0	0	0	0	
		0	0	0	0	
		0	0	0	<u> </u>	
		0	0	0	<u> </u>	
		0	0	0	<u> </u>	
		0	0		0	
- -		0		_	0	
H			0			
H		0	0	0	0	
		0	0	0	0	
		0	0	0	<u> </u>	
Ė		0	0	0	0	

980101

0050

(yyyy)

Protocol Nui	mber: NIDA-CPU-0003	Site Identification Number:	980101
RPR 102681	- Cocaine Interaction	Subject Identification Number:	0050
Study Day	UNSCHD		
		DEATH REPORT	
	Subject Date of Death	(mm) / (dd) / (yyyy)	
	Was autopsy performed? If yes, is autopsy report a	Yes No Unknown I Yes No	
	Is cause of death known? If yes, in the investigator's clinical judgement, where the second	nat was the primary cause of death?	
	Narrative description of death (include information	n about why cause of death is unknown, if applicable.)	
	Source	e Completed By (Initials):	
			DEATH v1

Protocol Number: NI	DA-CPU-0003		Site Identification Number:	980101
RPR 102681 - Cocain	ne Interaction	Π	Subject Identification Number:	0050
Study Day	JNSCHD	_	Date: /	/
		Form Not Done	(mm) (dd)	(уууу)
		DEMOGRAPHI	CS	
DEMOGRAPHIC	DATA			
1) <u>Gende</u>	<u>r</u> Male Female			
2) <u>Date o</u>	f Birth /	/ (mm/dd/yyyy)		
3) <u>Indica</u>	te which single major race/ethnici	ity applies:		
☐ Wh	nite, not of Hispanic Origin	American In	dian or Alaska native	
	spanic or Latino	Other, (spec		
	ican American, Black, not of Hispanic Or			
	an or Pacific Islander	Unknown		
4) <u>Ethnic</u>	ity/Race all that apply:	_		
For eac	h of the following, answer Yes to all that	t apply and No to those that do	not.	
Yes	No White			
Yes	No Black or African America	an		
Yes	No American Indian or Ala	skan Native		
Yes	No Spanish, Hispanic, or La	atino (check all that apply)		
	Mexican, Mexican-American, or	Chicano	an	
	Puerto Rican	Othe	er (specify)	
Yes	No Asian (check all that ap	pply)		
	Asian Indian	Kore	an	
	Chinese	Vietr	namese	
	Filipino	Othe	er (specify)	
	Japanese			
Yes	No Native Hawaiian or Paci	ific Islander (check all that apply	y)	
	Native Hawaiian	Sam	oan	
	Guamanian or Chamorro	Othe	er (specify)	
Yes	No Other (specify)			
<u>E</u>	Participant chooses not to answer			
EMPLOYMENT/S	SUPPORT STATUS			
1) <u>Educat</u>	tion completed (GED = 12 years):	(years)	(months)	
	employment pattern, past 30 days			
			Dart time (irregular hours, day)	work)
	Il time (35+ hours/week)	Part time (regular hours)	Part time (irregular hours, day v	WUIK)
	ndent	Military Service	Retired/Disabled	
□ Ho	memaker	Unemployed	In controlled environment	
3) Usual e	employment pattern, past 3 years	<u>::</u>		

4) Marital Status: Legally married Separated RUG/ALCOHOL USE		ving with partner/o	cohabitating		Vidowed lever Married		
SUBSTANCE	Days in Past	Lifetime			E OF ADMINIS		
Alcohol (any use at all)	30 Days	Years	oral	nasal	smoking	injection	N/A
and the second control of the second control							
	Ti Ti						
According to the interviewer, w	which substance is the		n? (Select	-	m.) of to intoxication		
Heroin Opiates/analgesics	Methado	one/LAAM (presc. rates)		done/LAAM (illici Hyp./Tranq./Benz		
Cocaine	Amphet	amines		Metha	mphetamine		

Protocol Number: NIDA-CPU-0003 RPR 102681 - Cocaine Interaction							Sit	e Identific	ation Number:	980101
					Subject Identification Number:				ation Number:	0050
Study Day	UNSC	CHD		<u> </u>			ı	Date:	/	/
					Form Not	Done		(mr	n) (dd)	(уууу)
					12 L	EAD ECG	i			
· ·	•	BNORMAL but does nued) participation		he subject	from partici	pation in the	e study, or A	BNORMAL SIG	GNIFICANT and	
	Test	Time	V R	PR	QT	QRS	R-R	QTc	ECG	
	Type	(00:00-23:59)	(bpm)	(msec)	(msec)	(msec)	(msec)	(msec)	Abnormal?	
	12-Lead								Yes No	
	If Abnor	। rmal, Clinically Sign	ificant?		Spec	। fy Abnormali	। ity as record	ed on ECG tra	acing	
		Yes No								
			Source Cor	mpleted B	y (Initials):				[ECG1 v1

Protocol Numb			Si	te Identifica	ation Number: 98	0101			
RPR 102681 - C		Subject Identification Number: 0050							
Study Day	UNSCHD			Form	Not Done [Date: (mm	/ (dd) /	уууу)
				1	12 LEAD E	CG			
,	esult was ABNORMA ontinued) participation			subject from p	participation in	the study, or a	ABNORMAL SIG	NIFICANT and	
Time Interval	Time (00:00-23:59)	VR (bpm)	PR (msec)	QT (msec)	QRS (msec)	R-R (msec)	QTc (msec)	ECG Abnormal?	
	If Abnormal, Cli	inically Signific	cant?		Specify Abno	rmality as reco	rded on ECG tra	Yes No	
	If Abnormal, Cli	inically Signifi	cant?		Specify Abnor	rmality as reco	orded on ECG tra	Yes No No No	
	If Abnormal, Cli	inically Signifi	cant?		Specify Abnor	rmality as reco	orded on ECG tra	Yes No No acing	
64 min	If Abnormal, Cli	inically Signific	cant?		Specify Abnor	rmality as reco	orded on ECG tra	Yes No No acing	
100 min	If Abnormal, Cli	inically Signifi	cant?		Specify Abno	rmality as reco	orded on ECG tra	Yes No No acing	

Protocol Number:	NIDA-CPU-0003			Site Identification Number:	980101
RPR 102681 - Coc	aine Interaction			Subject Identification Number:	0050
Study Day	UNSCHD				
		E	ND OF TRIAL		
1) <u>Study Terminat</u>	tion Date: (mm)	/ (dd) /	(yyyy) Las	t Date of Study Drug: (mm) / (dd)	/ (уууу)
2) Reason for stud	dy termination (CHECK ONLY	ONE):			
A. Subject	completed the study				
B. Subject	: was a screen failure				
	s checked, please check	primary reaso	n for screen failure	below (only check one)	
☐ He/	she did not meet study criter	ia			
	she did not complete screeni				
C. Subject	did not complete the study				
If "C" i	s checked, please check	primary reaso	n for withdrawal be	elow (only check one)	
Subj	ect was determined after enr	ollment to be ine	ligible. (Provide comm	ents)	
Subj	ect requested to withdraw. (Provide commen	ts)		
adve (If si	ect experienced intercurrent erse events, which, in the jud ubject experienced adverse pleted.) (Provide comments.)	dgement of the ir event(s), an Adv	nvestigator, prompted	early termination.	
	ect terminated for administra is category. Provide commer		clude protocol non-co	mpliance	
Subj	ect transferred to another tr	eatment progran	n (check type)		
	Methadone	LAAM	Drug Free	Inpatient Detox or Treatment	
	Therapeutic Community			Other, specify	
_ ·	ect was incarcerated.				
Subj	ect became pregnant.				
Subj	ect developed sensitivity to	study agent.			
Subj	ect was lost to follow-up.				
Subj	ect moved from area.				
Subj	ect died. (Complete Death R	eport CRF)			
Subj	ect can no longer attend clini	ic.			
Subj	ect no longer attends clinic.				
Subj	ect is in a controlled environr	ment.			
Othe	er (Provide comments)				

ENDTRIAL v1

Protocol Number: NIDA-CPU-0003	Site Identification Number:	980101
RPR 102681 - Cocaine Interaction	Subject Identification Number:	0050
Study Day UNSCHD		
	ENROLLMENT	
Is the subject eligible for the study based on Inclusion	ion and Exclusion Criteria?	
If yes:		
Was the subject enrolled?	es No	
If enrolled:		
Date enrolled (hospital admission date):	/ (mm/dd/yyyy)	
If eligible and not enrolled, check reason:		
failed to return		
declined participation		
other, specify:		
Source Completed By (Initials	s):	
	ENI	ROLL v1

	ocol Number: NIDA-CPU-0003 102681 - Cocaine Interaction	Site Identification Number: 98010 Subject Identification Number: 0050					
	y Day UNSCHD	Date:	//				
		(mm)	(dd)	(уууу)			
		EXCLUSION CRITERIA		7			
aı	ticipant must not:			J			
	Have a current or past history of seizure disorder, including al	Ichol- or stimulant-related seizure,					
	febrile seizure, or significant family history of idiopathic seizur	e disorder.	Yes	■ No			
	Have a previous medically adverse reaction to cocaine, include	ling loss of consciousness, chest pain, or seizure.	Yes	■ No			
	According to DSM-IV criteria as determines by structured cli						
	of major psychiatric illness, such as bipolar disorder, depressi dependence or disorders secondary to drug use as determine trained technician.		Yes	No.			
	Be pregnant or lactating.		Yes	■ No			
	Have a history of liver disease or current elevation of aspart.	ate aminotransferase (AST) or	- Vos				
	alanine aminotransferase (ALT) exceeding the upper limit of r	normal.	Yes	■ No			
	Have donated a unit of blood or participated in any other clir enrolling on the study.	nical investigation within 4 weeks of	Yes	No			
	Have a history of any illness, or a family history of early sign	· · · · · · · · · · · · · · · · · · ·	Yes	□ No			
	behavior, that in the opinion of the investigator might confourisk in administering the investigational agents to the subject.						
	Be seropositive for hepatitis B surface antigen, hepatitis C ar human immunodeficiency virus (HIV) type 1.	ntibody, or	Yes	■ No			
	Have a diagnosis of adult onset asthma (i.e., 21 years or older	er), or chronic obstructive					
	pulmonary disease (COPD), including those with a history of and those with current or recent (past 2 years) treatment wit	· · · · · · · · · · · · · · · · · · ·	Yes	No			
	Have any illness, condition, and use of medications, that in the admitting physician, would preclude safe and/or successful or		Yes	■ No			
	Currently use illicit drugs besides cocaine and marijuana.		Yes	■ No			
_	Have used any prescription drugs within 14 days of the start	or non-prescription drugs within 7 days of					
	the start of the study.		Yes	No			
	Be unable to distinguish between a 20 mg and 40 mg dose o administration of screening infusions.	of cocaine intravenously during the	Yes	■ No			
	Have had prior exposure to radiation for a research study. T	his excludes having x-rays for medical purposes.	Yes	No			
	Have had tattoos within the last 6 months.		Yes	No			
	Have a metallic body art (such as eye rings, navel rings) tha	at cannot be removed.	Yes	No			
	Have an abnormal MRI finding discovered as part of the PET (Subjects will be notified immediately of results and advised		Yes	□ No			

(EXCLUS v1)

Source Completed By (Initials):

Proto	col Number: NI	DA-CPU-000	3			Site Ident	ification Number:	980101
RPR 1	02681 - Cocain	e Interaction	1			Subject Ident	ification Number:	0050
Study	Day U	NSCHD		Forn	n Not Done	Date:	(mm) (dd)	(уууу)
				FOL	LOW-UP			
1)	Has contact bee		the subject?		O Yes O	No (If Yes, ski	p to Question #4)	
2)	If so, date		ntact been made with so	meone who c	(mm/dd/yyyy) an verify his/her stat	us?	○ Yes ○ N	0
	If yes, has the su	bject died?	O Yes O No	(If the subj	iect died, a Death Report (CRF must be completed)		
3)	If contact has not	been made with	the subject, explain:	Г				
4)	Does subject repo	rt use of any of	the following and if so,	for how man	y days in the last we	ek?	(Check all that apply).	
	DI	RUG	Days Used		DRUG	Days Used		
	Amp Benz Alcol	amphetamines hetamines odiazepines			Sedatives Nicotine Opiates Barbiturates None			
	Marij	uana			Other		(specify)	
5)	Does the subject r	eport currently i	eceiving treatment for d	rug or alcohol	l abuse/dependence?		○ Yes ○ N	0
6)	Does the subject rabuse treatment?	eport that he/sh	ne would take the study	drug again if	it were generally ava	ilable for substance	- Yes ON	o O Unknown
7)	Have any adverse	events occurre	<u>d?</u>	○ Yes	O No			
8)	Have any serious	adverse events	occurred?	OYes	○ No (If yes, a	Serious Adverse Event (CRF must be completed)	
9)	Additional comme	nts:						
		Source Comp	eted By (Initials):					FOLLOWUP v1

Protocol Num	ber: NIDA-CPU-00	003	Site Identification N	umber: 980101
RPR 102681 -	Cocaine Interacti	on	Subject Identification N	umber: 0050
Study Day	UNSCHD		Date: (mm)	(dd) (yyyy)
		INFUSION BLOO	D SPECIMEN TRACKING (DAY 0)	
	Actual Time (00:00 - 23:59)	Serum Prolactin Assay Blood Drawn	Comments	Initials
		○ Yes ○ No		
				INBLDSP1 v1

	r: NIDA-CPU-0003			Site Identification Number: 980101 Subject Identification Number: 0050					
Study Day	UNSCHD		ISION BI	LOOD SPECIME	N TRAC		Date: (mm) / (dd)	/ (уууу)	
Time Point	Actual Time (00:00 - 23:59)		Blood	Actual Time (00:00 - 23:59)		aine PK d Drawn	Comments	Initials	
-25 min		Yes	No		Yes	No			

INBLDSP2 v1

Prote	ocol Number: NIDA-CPU-0003	Site Identification Number:	980101
RPR	102681 - Cocaine Interaction	Subject Identification Number:	0050
Stud	y Day UNSCHD	Date: (mm) / (dd)	(уууу)
	INCLUSION CRI	TERIA	
Par	ticipant must:		
1.	Be volunteers who are not seeking treatment at the time of the study.	Yes	No
2.	Be between 18 and 45 years of age and within 20% of ideal body weight according Metropolitan Height and Weight Chart, and weigh at least 45 kg.	j to the	No
3.	Meet DSM-IV criteria for cocaine abuse or dependence.	Yes	■ No
4.	Must currently use cocaine by the smoked or i.v. route, and this use must be confirmation of the positive BE urine test once within 30 days prior to entering the study.	med by s	No No
5.	Be able to verbalize understanding of consent form, able to provide written informed and verbalize willingness to complete study procedures.	d consent,	No No
6.	If female and have a negative pregnancy test within 72 hours prior to receiving the investigational agent and agree to use one of the following methods of birth control, postmenopausal, or have had hysterectomy, or have been sterilized, or be male.	□Voc	■ No
	a) complete abstinence from sexual intercourseb) diaphragm and condom by partnerc) intrauterine device and condom by partnerd) sponge and condom by partner		
	<u>Note:</u> oral contraceptives, Depo-Provera, Norplant and intrauterine progesterone contraceptive system are not allowed.		
7.	Have a history and physical examination that demonstrate no clinically significant co- for participating in the study.	ntraindication	No No
8.	Be able to comply with protocol requirements, Clinical Pharmacology Unit (CPU) rul and be likely to complete all the study treatments.	es and regulations,	■ No
	To be included in the trial, all answers to Inclusion	on Criteria must he VFS	
		an orneria must be 123	
	Source Completed By (Initials):		(INCLUS V1)

Protocol Number: NIDA-CPU-0003	Site Identification Number:	980101
RPR 102681 - Cocaine Interaction	Subject Identification Number:	0050
Study Day UNSCHD		
	INFORMED CONSENT DATE	
Date Informed Consent was	s signed: (mm) / (dd) / (yyyy)	
Completed by ((initials):	
		INCONSNT v1

	CPU-0003	Site I	dentification	Number:	980101		
RPR 102681 - Cocaine In	teraction	Subject I	Subject Identification Number:				
Study Day UN	SCHD	Da	te:	/	/		
			(mm)	(dd)	(yyyy)		
	INFUSION B	OOD SPECIMEN TRACKING (DAY 13, 2	PO AND 27)		\neg		
	1141 001014 DI	SOD SI ESIMEN TRACKING (BAT 13, 2	O AIVD 21)				
Actual Time	RPR 102681PK	Comments		Initials			
(00:00 - 23:59)	Blood Drawn						
12:12	Yes No						
12:12	Yes No				<u> </u>		
12:12							

rotocol Number	r: NIDA-CPU-0003	3			Site Id	entification	Number:	980101
PR 102681 - Co	caine Interaction			Subject Identification Number:				0050
tudy Day	UNSCHD				Date	(mm)	/ (dd)	(уууу)
	IN	FUSION BL	LOOD SP	ECIMEN TRACK	NG (DAY 14, 21	AND 28)		
-								
Time Point	Actual Time (00:00 - 23:59)	RPR 1026 Blood D		Comments				Initials
-20 min		Blood D		Comments				Initials
		Blood D	Drawn	Comments				Initials

Protocol Number: NIDA-CPU-0003	Site Identification Number:	980101
RPR 102681 - Cocaine Interaction	Subject Identification Number:	0050
Study Day UNSCHD	Date: (mm) / (dd)	/ <u>(yyyy)</u>

INFUSION BLOOD SPECIMEN TRACKING (DAY 15, 22 AND 29)

Time Point	Actual Time (00:00 - 23:59)	LFT B		Actual Time (00:00 - 23:59)	Cocai Blo Dra	od	Actual Time (00:00 - 23:59)	RP 1026 Blo Dra	81PK ood	Actual Time (00:00 - 23:59)	Prola Ass	rum actin say Drawn	Comments	Initials
		Yes	No		Yes	No		Yes	No		Yes	No		

INBLDSP5 v1

Protocol Number: NIDA-CPU-0003	Site Identification Number: 980101
RPR 102681 - Cocaine Interaction	Subject Identification Number: 0050
Study Day UNSCHD	
	Form Not Done
	INFECTIOUS DISEASE ASSESSMENT
Indicate whether the laboratory value is	NEGATIVE: negative test result, POSITIVE: but DOES NOT EXCLUDE subject from
participation or continued study participal	ion, POSITIVE SIGNIFICANT: significant during screening means subject is ineligible
	eans consider reporting result as adverse event if unexpected and at least possibly rmination of the subject from study, INDETERMINANT: result was not interpretable.
Date of Hepatitis Specimen:	/ (mm/dd/yyyy)
<u>Infectious Disease</u>	Provide comments for any abnormal Result value
Hepatitis B surface antigen result	
Hepatitis B surface antibody result	
Hepatitis B core antibody result	
Hepatitis C virus antibody result	
Date PPD test administered	/ (mm/dd/yyyy)
Time PPD test administered	(00:00 - 23:59)
Date PPD test read	/ (mm/dd/yyyy) PPD Previously Positive
Time PPD test read	*(Test not done, chest X-ray required)
PPD test result	*If positive, chest X-ray required.
If test not done, state reason.	
Provide comments for any positive value.	
Date chest X-ray performed	/ (mm/dd/yyyy)
Results of chest X-ray	
If chest X-ray not done, state reason.	
Provide comments for any abnormal finding	J.
Source Completed By (Initials):	
Source completed by (mittals):	INFECDIS v1

Protocol Number: NIDA-CPU-00				Site Identification	
RPR 102681 - Cocaine Interacti Study Day UNSCHD	on T			Subject Identification Date:	Number: 0050
Study Buy		Forn	n Not Done	(mm)	(dd) (yyyy)
		IN	NFUSION MON	IITORING	
	Cocaine	20mg/Saline	Coca	ine 40mg/Saline	
Infection 4. Short Times					4.D.,
Infusion 1: Start Time	(00:00 -		Time:	Administere 00:00 - 23:59)	(Initials)
Infusion 2: Start Time	(00:00 -		Time:	Administere 00:00 - 23:59)	d By: (Initials)
Time Interval	Actual Time	Blood Pressure	Heart Rate	Comments	Initials
-15 min	(00:00-23:59)	(sys) / (dias)	(beats/min)		
	ı				

15 min	(00:00-23:59)	(sys) (dias)	(beats/min)		
54 min	(00:00-23:59)	(sys) (dias)	(beats/min)		
					<u> </u>
	1	1	1	1	1

00.			_			
90 min	(00:00-23:59)	(sys)	(dias)	(beats/min)		
	(00:00 20:07)	(5)5)	(dido)	(20dto/IIIII)		
		ļ J				<u> </u>
					-	
						<u>-</u>
				ļI		
				<u> </u>		
				<u> </u>		

Protocol Number: NI	DA-CPU-0003			Site Identification	Number:	980101
RPR 102681 - Cocain	ne Interaction			Subject Identification	Number:	0050
Study Day	UNSCHD			Date: (mm)	(dd)	(уууу)
INTAKE SCREENING LAB TRACKING FORM						
Check to indic	ate whether tests were	done.				
				Comments		
Chemistry plus L	iver function tests	Not Done	Done			
	Source Com	pleted By (Initials)	: [П	NLABTRK v1

Protocol Nu	mber: NIDA-CPU-00	03		Site Ide	ntification Nun	nber: 980101
RPR 102681 - Cocaine Interaction				Subject Ide	ntification Nun	nber: 0050
Study Day	UNSCHD		Form Not Done	Date Administered		(dd) (yyyy)
		INVESTIGAT	IONAL AGENT ADI	MINISTRATION		
Line No.	No. of Capsules Administered	RPR 102681/ Placebo Dose	Time Administered	Comments		Administered By
1.			(00:00-23:59)			(Initials)
2.			(00:00-23:59)			(Initials)
	Source Co	mpleted By (Initials):				INVAGT v1

Protocol Number: NIDA-CPU-0003				Site Identification	Number:	980101
RPR 102681 - Cocaine Interaction	<u> </u>]		Subject Identification	Number:	0050
Study Day UNSCHD		_		Date: (mm)	(dd)	(уууу)
	LA	AB TRACI	KING FORM			
Check to indicate whether test	s were done.					
				Comments		
Hematology	○ Not	Done	○ Done			
Chemistry plus Liver function tests	○ Not	Done	○ Done			
S	ource Completed	By (Initials	s):			LABTRACK v1

	Protocol Number: NIDA-CPU-0003 Site Identification Number: 980101 RPR 102681 - Cocaine Interaction Subject Identification Number: 0050									
Stud	ly Day UNSCHD		<u></u>			Date: / / (yyyy)				
	MEDICAL HISTORY									
	<u>Disorder</u>	Yes excludes	Yes doesn't exclude	<u>No</u> history of disorder	<u>Not</u> evaluated	If yes, specify or describe				
1.	Allergies: drug									
2.	Allergies: other, specify									
3.	Sensitivity to Agent/Compounds									
4.	History of Asthma									
5.	HEENT									
6.	Cardiovascular									
7.	Renal									
8.	Hepatic									
9.	Pulmonary									
10.	Gastrointestinal									
11.	Musculoskeletal									
12.	Neurologic									
13.	Psychiatric									
14.	Dermatologic									
15.	Metabolic									
16.	Hematologic									
17.	Endocrine									
18.	Genitourinary									
19.	Reproductive System									
20.	Seizure									
21.	Infectious Disease									
22.	Other 1, specify:									
23.	Other 2, specify:									

24. Was major surgery ever performed? No (If Yes, list surgeries:)							
			Is surgery rele	vant to study participati	on?		
<u>Type of Surgery</u>		of Surgery	<u>Yes</u>	<u>Yes</u>			
	(mm/	/dd/yyyy)	<u>excludes</u>	doesn't exclude	No		
25.	_	′					
26.		/					
27.		/					
28.		/					
29.		/					
30.	/	/					
31.		/					
TOBACCO HISTORY							
32. Has subject used any tobacco product (e.g. cigarettes, cigars,	pipe, chewing toba	cco) in the past weel	<i><</i> ?	Yes No			
33. Has subject ever used any tobacco product for at lea	st one year?			Yes No			
34. If yes, number of years tobacco used?				<u> </u>			
COMMENTS							
Source Completed By (Initials): MEDHIST v1							

Protocol Number: NIDA-CPU	-0003				Site Identification Number: 980101					
RPR 102681 - Cocaine Interac	ction			9	Subject Identification Number: 0050					
Study Day UNSCHD					Date: / / / / (yyyy)					
	PHYSICAL EXAMINATION									
Height: inches centimeters Weight: pounds kilograms										
Height:	indica	Continuetors	weight	·	pounds kilograms					
Temperature: (oral)		F C	Respira	tory Rate	<u>e</u> breaths/minute					
Pulse Rate		beats/minute	Blood P	ressure	/ mm/hg					
General Exam	<u>Normal</u>	<u>Abnormal</u>	Abnormal Significant	<u>Not</u> <u>Done</u>	If Abnormal, explain below					
Oral (mouth)										
Head										
Eyes, ears, nose/throat										
Cardiovascular										
Lungs										
Abdomen (include liver/spleen)										
Extremities										
Skin										
Neuropsychiatric mental status										
Neuropsychiatric sensory/motor										
Musculoskeletal										
General Appearance										
Other, specify:										
So	urce Completed	By (Initials):								
	·				PHYSEXAM v1					

Protocol Number: NIDA-CPU-0003	Site Identification Number: 980101
RPR 102681 - Cocaine Interaction	Subject Identification Number: 0050
Study Day UNSCHD	
P	LASMA ALCOHOL TEST
<u> </u>	
Diasma A	Icohol Test Done Not Done
Plasilia A	iconorrest
	If done:
	Date: / / / / / / / / / / / / / / / / / / /
	(mm) (dd) (yyyy)
Source Cor	mpleted By: (initials)
	PLASMA v1

Protocol Number: NIDA-CPU-0003		Site Identification Number:	980101			
RPR 102681 - Cocaine Interaction		Subject Identification Number:	0050			
Study Day UNSCHD	Form Not Done	Date: (mm) / (dd)	(уууу)			
	PROFILE OF MOOD STATES (POMS)					

How have you been feeling during the past two days?

	Not	A Little		Quite	
<u>FEELINGS</u>	at all	Bit	Moderately	a bit	Extremely
1. Friendly	0	1	2	3	4

31. Annoyed	0	1	2	3	4

Protoc	ol Num	nber: NIDA-CPU-0	0003				Site Ident	ification Num	ber: 980101
RPR 1	02681 -	Cocaine Interact	tion			Su	ıbject Ident	ification Num	ber: 0050
Study	Day	UNSCHD					Date:	(mm) /	(dd) (yyyy)
					PREGNAN	ICY]	
1)	Was a	pregnancy test per	formed?	O Yes					
				O No O N/A	subject is ma	le (If N/A, the rest of the	he form should	be blank)	
2)	Pregna	ancy test result:		O Positiv					
3)	<u>Pregna</u>	ncy test comments	<u>s:</u>	() mga					
4)	Is the s	subject lactating?		○ Yes	○ No	Not Applicable			
5)	Is the s	subject using an ac	ceptable method of	<u>birth cont</u>	trol?	○Yes	O No		
6)	What n	method of birth con	trol is the subject us	sing?					
		Subject is pos	stmenopausal						
		Subject had a	a hysterectomy						
		Subject is ster	rile						
		O Complete abst	tinence from sexual into	ercourse					
		O Diaphragm an	nd condom by partner						
		O Intrauterine d	device and condom by p	partner					
		Sponge and c	condom by partner						
		Sou	urce Completed By (Initials):					PREGNANT v1

Protocol Numi	ber: NIDA-CPU-00	03		Site Identification Number: 980	101
RPR 102681 - 0	Cocaine Interaction	n		Subject Identification Number: 00	050
Study Day	UNSCHD				
		PRIOR AND COI	NCOMITANT MEDICATION	S	
Has the subject	taken any prescrip	tion or OTC medications 30) days prior to or during the stu	Yes No If yes, pleas	
Dose	Unit	of Medication	Frequency	Route of Administration	
Strength of Medication	CAP = capsule g = gram GR = grain GTT = drop ug = microgram uL = microliter mg = milligram mL = milliliter OZ = ounce	PUF = puff SPY = spray/squirt SUP = suppository TSP = teaspoon TBS = tablespoon TAB = tablet UNK = unknown OTH = other, specify	ONCE = single dose QD = once daily BID = twice daily TID = three times a day QID = four times a day QOD = every other day PRN = as needed OTH = other, specify QHS = at bedtime	PO = oral AUR = auricular TD = transdermal IA = intra-articula INH = inhaled NAS = nasal IM = intramuscular IO = intraocular IV = intravenous UNK = unknown REC = rectal OTH = other, specification VAG = vaginal SQ = subcutaneous SL = sublingual	
No. Medi	ication	Dose	Unit Other I	Frequency Other Route O	ther
1					
			(specify)	(specify) (sp	pecify)
Star	rt Date	Stop Date	Cont.? Indication	Related to an AE?	nitials
(mm) /	/ (yyyy)	(mm) (dd) (yyy	у)	Yes No	

Protocol Number: NIDA-CPU-0003	Site Identification Number: 980101
RPR 102681 - Cocaine Interaction	Subject Identification Number: 0050
Study Day UNSCHD	Date: / (dd) / (yyyy)
PRE-INTAKE	SCREENING LAB TRACKING FORM
Check to indicate whether tests were don	
	Comments
Hematology	lot Done O Done
Chemistry plus Liver function tests	lot Done
Urinalysis	lot Done
Source Comple	red By (Initials):
	PRLABTRK v1

Protocol Number: NIDA-CPU-0003	Site Identification Number:	980101
RPR 102681 - Cocaine Interaction	Subject Identification Number:	0050
Study Day UNSCHD	_	
	RANDOMIZATION	
Was the subject randomized?	ves No	
If randomized:		
Date randomized:	/ (mm/dd/yyyy)	
Random Dose Code Number:		
If randomized, did the subject receive	e the first dose of study drug?	
If eligible and not randomized, check reason:		
declined participation	other, specify:	
Source Completed By (Initials		
Source completed by (Illitials	a).	
	RAN	IDOM v1

Protocol Number: NIDA-CPU-00	03			Site Identifica	tion Number:	980101
RPR 102681 - Cocaine Interactio	n	7	Sub	ject Identifica	tion Number:	0050
Study Day UNSCHD						
		SERIOUS ADV	ERSE EVENTS			
DEMOGRAPHIC INFORMATION						
Enrollment Date	/ /	(mm/dd/yyyy)	<u>Gender</u>	Male	Female	
Date of Birth	/ /	(mm/dd/yyyy))			
Race						
White, not of Hispanic Origin		American Indian or A	Alaska native			
Hispanic or Latino		Other, (specify):				
African American, Black, not of His	panic Origin					
Asian or Pacific Islander		Unknown				-
Height Inche	es centimeters	<u>We</u>	<u>ight</u>	pounds	kilograms	_
AE/Diagnosis:						
SERIOUS ADVERSE EVENT						
SAE Description						
Onset Date /	/	(mm/dd/yyyy)				
Reported to FDA by:		Initial Date rep	ported to FDA:	/	/	— (mm/dd/yyyy)
Reported to Sponsor by:		Date reported	to sponsor:	/	/	_ (mm/dd/yyyy)
Reported to NIDA by:		Initial Date rep	oorted to NIDA:	/	/	— (mm/dd/yyyy)
Severity grade mild	moderate	severe				_
Was SAE related to investigat	ional agent?					
definitely prol	possibly	remotely	definitely not	ınknown		
Action taken regarding invest	igational agent		Other action(s	s) taken		
none	reduced dose	9	none			
discontinued permanently	increased do:	se	remedial thera	py - pharmacologic		
discontinued temporarily	delayed dose	e	remedial thera	py - nonpharmacolo	gic	
			hospitalization	(new or prolonged)		
Outcome If outcome was death,	a Death Report Form mu	st be completed.				
death	disability					
life-threatening event	congenital	anomaly				
hospitalization	other (spec	cify)				
Concomitant Medications						

Relevant history is smoking and alcolong and short and s	nol use, hepatic/renal dysfunc	conditions (e.g., allergies, pregnancy,				
INVESTIGATIONAL	AGENT ADMINISTRATION agent information known?	(IIIIII dd.) Jyyyy				
Unit Code		Other unit				
Start date	(mm) (dd) (yyyy) Stop date (mm) (dd) (yyyy) or continuing					
Rout	e of administration	Frequency				
auricular inhaled intra-articular intramuscular intraocular intravenous nasal oral	rectal subcutaneous sublingual transdermal vaginal unknown other (specify)	single dose once daily every other day twice daily three times a day four times a day as needed other (specify)				
Comments						
	Source Com	npleted By (Initials):				

Protocol Number: NIDA-CPU-0003	Site Identification Number: 980101
RPR 102681 - Cocaine Interaction	Subject Identification Number: 0050
Study Day UNSCHD	Date: / / / / / / / / / / / / / / / / / / /
	SCID WORKSHEET
AXIS I - Diagnosis	
	AST Substance Abuse or Dependence Diagnoses, HER PAST Diagnoses (Include DSM-IV code).
Line Axis I DSM- No. Diagnoses Type Cod	S Company of the comp
Source Completed By (Initials):	SCID v1

Protocol Number	er: NIDA-CPU-0003		Site	Identification Num	980101
RPR 102681 - Ce	ocaine Interaction		Subject	Identification Num	ober: 0050
Study Day	UNSCHD		Da	ate: mm) /	/ (yyyy)
		Form Not Do	one 🗌	(11111) (6	uu) (yyyy)
	U	RINE TOXICO	LOGY		7
<u>Urine tem</u>	perature within expected range?	Yes	No Unk	nown (96.4 < or =	T < or = 100.4 F)
	Drug/Test	<u>Positive</u>	<u>Negative</u>	Not Done	
	Amphetamines				
	Barbiturates				
	Benzodiazepines				
	Cannabinoids (THC)				
	Cocaine metabolites				
	Methadone				
	Methamphetamine				
	Methaqualone				
	Opiates				
	Phencyclidine (PCP)				
	Propoxyphene				
	Tricyclics				
	Source Comp	leted By (Initials)	:	-	

URINETOX v1

Protocol Numb	ber: NIDA-CPU-0	0003		Site Identification Num	980101
RPR 102681 - 0	Cocaine Interact	tion		Subject Identification Num	ober: 0050
Study Day	UNSCHD		Form Not Done	Date: / / / (mm)	/ (yyyy)
			VISUAL ANALOG SCALE		
		Do you feel any dru	g effect?		
	_	2. How high are you?			
	_	3. Does the drug have	any good effects?		
	_	4. Does the drug have	any bad effects?		
		5 How much do you lik	ce the drug?		
		6. How much do you do	esire the drug right now?		
		7. How depressed do y	rou feel?		
		8. How anxious do you	feel?		
	_	9. How stimulated do y	ou feel?		
		10. If you had access to	the drug right now,		
		how likely would you	u be to use it?		
		11. How much would yo	u pay for this drug?	\$	
		Source Completed I	By (Initials):		VAS v1

Protocol Nun	nber: NIDA-CPU-0003		Site Identification Number:	980101
RPR 102681 -	· Cocaine Interaction		Subject Identification Number:	0050
Study Day	UNSCHD	Form Not Done	Date: (mm) / (dd)	/ (yyyy)

VISUAL ANALOG SCALE

	Actual Time (00:00 - 23:59)	Any drug Effect?	High?	Good Effects?	Bad Effects?	Liking?
Time Interval						
-15 Minutes	Desire for Drug?	Depressed?	Anxious?	Stimulated?	Likely to Use?	Pay for Drug?
	Actual Time (00:00 - 23:59)	Any drug Effect?	High?	Good Effects?	Bad Effects?	Liking?
Time Interval						
5 Minutes Post	Desire for Drug?	Depressed?	Anxious?	Stimulated?	Likely to Use?	Pay for Drug?
	Actual Time (00:00 - 23:59)	Any drug Effect?	High?	Good Effects?	Bad Effects?	Liking?
Time Interval						
15 Minutes Post	Desire for Drug?	Depressed?	Anxious?	Stimulated?	Likely to Use?	Pay for Drug?
	Actual Time (00:00 - 23:59)	Any drug Effect?	High?	Good Effects?	Bad Effects?	Liking?
Time Interval						
25 Minutes Post	Desire for Drug?	Depressed?	Anxious?	Stimulated?	Likely to Use?	Pay for Drug?
	Actual Time (00:00 - 23:59)	Any drug Effect?	High?	Good Effects?	Bad Effects?	Liking?
Time Interval						<u> </u>
35 Minutes Post	Desire for Drug?	Depressed?	Anxious?	Stimulated?	Likely to Use?	Pay for Drug?

	Actual Time	Any drug	High?	Good	Bad	Liking?
	(00:00 - 23:59)	Effect?		Effects?	Effects?	
Time Interval			<u> </u>		<u> </u>	
	Desire for	Depressed?	Anxious?	Stimulated?	Likely	Pay for
	Drug?				to Use?	Drug?
	Actual Time	Any drug	High?	Good	Bad	Liking?
	(00:00 - 23:59)	Effect?		Effects?	Effects?	
Time Interval					<u> </u>	
75 Minutes Post	Desire for	Depressed?	Anxious?	Stimulated?	Likely	Pay for
	Drug?				to Use?	Drug?
	Actual Time	Any drug	High?	Good	Bad	Liking?
	(00:00 - 23:59)	Effect?		Effects?	Effects?	
Time Interval			<u> </u>		<u> </u>	
85 Minutes Post	Desire for	Depressed?	Anxious?	Stimulated?	Likely	Pay for
	Drug?				to Use?	Drug?
	<u> </u>					
	Actual Time	Any drug	High?	Good	Bad	Liking?
	(00:00 - 23:59)	Effect?		Effects?	Effects?	
Time Interval		<u> </u>	<u> </u>			<u> </u>
95 Minutes Post	Desire for	Depressed?	Anxious?	Stimulated?	Likely	Pay for
	Drug?				to Use?	Drug?

VISLANA1 v1

Source Completed By (Initials):

Protocol Number: NIDA-CPU-0003				Site Identificatio	n Number:	980101
RPR 102681 - Cocaine Interaction				Subject Identificatio	n Number:	0050
Study Day UNSCHD		Form Not D	one 🗌	Date: (mm)	/ (dd)	(уууу)
		VITAL S	IGNS			
	Time:	Г		(00:00-23:59)		
	Temp: (oral)			F C		
	SITTING:					
	Respiratory	Rate		breaths/minute		
	Pulse Rate			beats/minute		
	Blood Pressu	ire		/ mm/hg		
Source Completed By (nitials):					VITALS v1

rotocol Number: NIDA-CPU-					tification N		0101
PR 102681 - Cocaine Interac	tion		Suk	•	tification N		001
udy Day UNSCHD	_			Date:	(mm)	/ (dd)	(уууу)
		Form	Not Done		,	,	(,,,,,
		CHE	MISTRIE	S			
<u>Analyte</u>	<u>Std.</u> Quantity	<u>Standard</u> <u>Unit</u>	Other Specify	<u>Normal</u>	Abnormal	Abnormal Significant	<u>Not</u> <u>Done</u>
1) GGT				0	0	0	0
2) LDH				0	0	0	0
3) SGOT/AST				0	0	0	0
4) SGPT/ALT				0	0	0	0
5) AlkPhos				0	0	0	0
6) Total Bilirubin				0	0	0	0
7) Total Protein				0	0	0	0
8) Albumin				0	0	0	0
9) CPK			Ī	0	0	0	0
10) Glucose			1	0	0	0	0
11) BUN				0	0	0	0
12) Creatinine				0	0	0	0
13) Uric Acid				0	0	0	0
14) Calcium				0	0	0	0
15) Phosphorus				0	0	0	0
16) Sodium				0	0	0	0
17) Potassium			ī —	0	0	0	0
18) Chloride				0	0	0	0
19) CO2				0	0	0	0
20) Cholesterol			T	0	0	0	0
21) Triglycerides			T T	0	0	0	0
, 3,			ī	0	0	0	0

Protocol Number: NIDA-C	PU-0003		_	Sit	e Identificat	tion Number	980101
RPR 102681 - Cocaine Inte	eraction			Subjec	t Identificat	ion Number	0001
Study Day UNSCHD					Date: (mr	n) (dd)	/ (уууу)
			Form Not D	one 🗌	(1111	ii) (dd)	(3333)
		<u> </u>	HEMATOL	_OGY			
<u>Complete</u> <u>Blood Count</u>	Std. Quantity	<u>Standard</u> <u>Unit</u>	Other Specify	<u>Normal</u>	Abnormal	Abnormal Significant	<u>Not</u> <u>Done</u>
1) WBC							
2) RBC							
3) Hemoglobin							
4) Hematocrit							
5) MCV							
6) Platelet Count							
7) Neutrophils							
8) Lymphocytes							
9) Monocytes							
10) Eosinophils							
11) Basophils							
Provide comments for an Source Completed By (I	_	value(s)					HEMA v1

Protocol Number: NIDA-CP	PU-0003		Site Identification Number: 980101
RPR 102681 - Cocaine Inter	raction		Subject Identification Number: 0001
Study Day UNSCHD			Date: / / / / / / / / / / / / / / / / / / /
	F	orm Not Done	(mm) (dd) (yyyy)
		URINALYSIS	
Indicate whether the laborato significant, ABNORMAL SIGNI		vithin normal limits, ABNO	RMAL: outside of normal limits but not clinically ject is ineligible for study.
	Levels	Result	Comments for Abnormal Values
1) Color			
2) Clarity			
3) Specific Gravity			
4) PH			
5) Protein			
6) Glucose			
7) Ketones			
8) Bilirubin			
9) Blood			
10) Leukocyte Esterase			
11) Nitrite			
12) Urobilinogen (mg/dl)			
13) WBC			